Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P326.

The association between inflammatory bowel disease (IBD) and parity

Authors:

A. Shitrit1, M. Shaubi2, T. Adar1, B. Koslowsky1, E. Goldin1, S. Granovsky-Grisaru3, 1Shaare Zedek Medical Center, Digestive diseases institute, Jerusalem, Israel, 2Shaare Zedek Medical Center, Department of Obstetrics and gynecology, Jerusalem, Israel, 3Shaare Zedek Medical Center, Department of obstetrics and gynecology, division of maternal fetal medicine, Jerusalem, Israel

P326. Decreasing rates of hospital admissions for inflammatory bowel disease between 2000 and 2009
P326. Prevention of recurrence after surgery of Crohn's disease: Efficacy of adalimumab
P326. Use of anti-TNF-alpha therapy in Crohn's disease patients in clinical practice: results of a nation-wide survey (named CROSSOVER) conducted in Spain
Authors:

A. Gutierrez1, I. Marín-Jiménez2, E. Ricart3, J. Hinojosa4, 1Hospital General Alicante, Alicante, Spain, 2Hospital Gregorio Marañón, Madrid, Spain, 3Hospital Clínic-CiberEHD, Barcelona, Spain, 4Hospital Manises, Valencia, Spain

P326

Three-year steroid free remission and safety of azathioprine treatment in inflammatory bowel disease patients.

Authors:

C. Cassieri*, R. Pica, E.V. Avallone, C. Corrado, M. Zippi, P. Vernia, P. Paoluzi, E.S. Corazziari

"Sapienza" University, Internal Medicine and Medical Specialties, Rome, Italy

P327.

The value of social media in inflammatory bowel diseases

Authors:

J.M. Choi, W.K. van Deen, L. Nguyen, A. Zand, M. Berns, N. Duran, D.W. Hommes, M.G. van Oijen, UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, Los Angeles, United States

P327. Efficacy of a new antimesenteric functional end-to-end anastomosis for prevention of surgical recurrences after resection for Crohn's disease: A multicenter study in Japan and the United States
P327. Mortality from inflammatory bowel disease in a healthcare area of Gijon, Spain: Results from the study of a hospital registry from 1992 to 2006
P327. Unravelling the mechanism of action of infliximab in Crohn's disease and healthy controls following in vitro culture with blood-enriched dendritic cells
Authors:

S. Peake1, D. Bernardo2, E. Mann2, J. Landy1, H. Omar2, S. Knight2, A. Hart1, 1St Mark's Hospital, IBD Unit, Harrow, United Kingdom, 2Imperial College, APRG, London, United Kingdom

P327

Colorectal cancer in IBD patients treated or untreated with anti-TNFs: A retrospective matched-pair study in a 14 years follow up

Authors:

M. Ascolani*1, C. Petruzziello1, G. Sica2, A. Ruffa1, S. Onali1, E. Calabrese1, E. Lolli1, F. Pallone1, L. Biancone1

1Università di Roma Tor Vergata, Medicina dei sistemi, cattedra di Gastroenterologia, Roma, Italy, 2Università di Roma Tor Vergata, Chirurgia, Roma, Italy

P328.

The use of IVIG in IBD patients with contraindications or who are unresponsive to conventional treatment for inflammatory bowel disease

Authors:

S. Merkley1, S. Horst2, D. Beaulieu2, C. Duley2, K. Annis2, A. Nohl2, D. Schwartz2, 1University of Kentucky, Department of Medicine. Division of Gastroenterology, Hepatology, and Nutrition, Lexington, United States, 2Vanderbilt University, Department of Medicine. Division of Gastroenterology, Hepatology, and Nutrition, Nashville, United States

P328. Multiple short-term dose intensifications are effective in Crohn's disease patients treated with adalimumab
P328. Revaluation of risk factors for inflammatory bowel diseases according to the “hygiene hypothesis”: A South-Italian, case–control, multi-centre prospective study
P328. Understanding sexual activity and satisfaction in inflammatory bowel disease. Development and validation of a short self-administered assessment tool
Authors:

E. McDermott1, D. Keegan1, K. Byrne1, G. Cullen1, G. Doherty1, K. Malone2, H. Mulcahy1, 1St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 2St Vincent's University Hospital, Department of Psychiatry, Dublin, Ireland

P328

P-glycoprotein 170 (P-GP) functional activity in peripheral blood lymphocytes (PBL) of IBD patients during treatment with anti-TNFs

Authors:

A. Sambuelli*1, C. Cortada2, A. Gil1, S. Negreira1, M. Bellicoso1, S. Huernos1, P. Tirado1, P. Chavero1, S. Goncalves1

1IBD Section - Hospital Bonorino Udaondo, Medicine, Buenos Aires, Argentina, 2Centro de Biologia Molecular (CDM), Flow Cytometry, Buenos Aires, Argentina

P329. First explicit criteria to decide on the appropriateness of therapy of ulcerative colitis: The European EPATUC Panel
P329. Large scale genomic instability in patients with colorectal cancer in inflammatory bowel disease – Association with clinico­histological factors and survival
P329. Tuberculosis infection in patients with inflammatory bowel diseases receiving anti-TNF agents: report of a case series of 99 patients
Authors:

A. Hernandez Camba1, H. Izaguirre2, I. Alonso1, M. Carrillo1, L. Ramos1, H. Gonzalez2, E. Quintero1, 1Hospital Universitario de Canaris, Gastroenterology, La Laguna, Spain, 2Hospital Universitario de Canaris, Pneumology, La Laguna, Spain

P329

Intermittent vancomycin and gentamicin as exclusive therapy for severe very early onset Inflammatory Bowel Disease

Authors:

R. Lev-Tzion, O. Ledder, E. Shteyer, D. Turner*

Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel

P330.

The impact of peri-operative administration of infliximab on the healing process of intestinal anastomosis: A rat experimental study

Authors:

I. Papaconstantinou1, C. Zeglinas2, M. Gazouli3, C. Nastos1, A. Yiallourou1, A. Papalois4, C. Tzathas2, 1Areteion Hospital, Medical School, University of Athens, 2nd Department of Surgery, Athens, Greece, 2Tzaneio General Hospital, Department of Gastroenterology, Piraeus, Greece, 3School of Medicine, University of Athens, Laboratory of Histology and Embryology, Athens, Greece, 4ELPEN-Pharmaceuticals Co. Inc, Experimental-Research Unit, Pikermi Attikis, Greece